| Should Edwards Lifesciences Stock Remain in Your Portfolio Now? |
EW stock is on investors' radars due to the promising structural heart opportunities and impressive TMTT portfolio. |
zacks.com |
2025-05-16 11:36:04 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference |
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible lat. |
businesswire.com |
2025-05-06 11:05:00 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens |
Edwards Lifesciences‘ EW shares are trading higher Thursday after the company reported first-quarter 2025 sales of $1.41 billion. |
benzinga.com |
2025-04-24 18:42:49 |
Czytaj oryginał (ang.) |
| EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised |
Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease. |
zacks.com |
2025-04-24 11:45:28 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences Corporation (EW) Q1 2025 Earnings Call Transcript |
Edwards Lifesciences Corporation (NYSE:EW ) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Company Participants Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - Global Leader, TMTT Larry Wood - Global Group President, TAVR and Surgical Conference Call Participants Larry Biegelsen - Wells Fargo David Roman - Goldman Sachs Travis Steed - Bank of America Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Matt Taylor - Jefferies Joanne Wuensch - Citibank Pito Chickering - Deutsche Bank Chris Pasquale - Nephron Patrick Wood - Morgan Stanley Operator Greetings, and welcome to the Edwards Lifesciences First Quarter 2025 Results. [Operator Instructions] As a reminder, this conference is being recorded. |
seekingalpha.com |
2025-04-24 01:35:33 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences (EW) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates |
The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-04-23 23:00:38 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences raises 2025 sales forecast after robust quarter |
Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment. |
reuters.com |
2025-04-23 21:43:48 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences Delivers In-Line Sales, Narrow Profit Beat |
Edwards Lifesciences stock was flat late Wednesday after the medtech company beat profit views and delivered in-line sales. |
investors.com |
2025-04-23 20:41:59 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences Reports First Quarter Results |
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1 Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth Q1 EPS of $0.622; adjusted1 EPS of $0.64 SAPIEN M3 CE Mark approval uniquely positions Edwards with a comprehensive TMTT p. |
businesswire.com |
2025-04-23 20:15:00 |
Czytaj oryginał (ang.) |
| Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics |
Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. |
zacks.com |
2025-04-18 14:20:50 |
Czytaj oryginał (ang.) |
| Eight-Year Data Confirm Long-Term Durability of Edwards' RESILIA Tissue |
CAIRO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves. For more than 65 years, Edwards has been the leader in heart valve innovations. To create a more durable heart valve, Edwards developed the RESILIA tissue technology more than two d. |
businesswire.com |
2025-04-18 12:00:00 |
Czytaj oryginał (ang.) |
| Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings |
EW's first-quarter 2025 performance is likely to have gained from growth drivers across its businesses amid macroeconomic headwinds. |
zacks.com |
2025-04-17 13:35:40 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025 |
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards L. |
businesswire.com |
2025-04-16 11:05:00 |
Czytaj oryginał (ang.) |
| Edwards SAPIEN M3 Receives CE Mark, Becoming World's First Transfemoral Transcatheter Mitral Valve Replacement System |
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company's SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the company's SAPIEN technology, the SAPIEN M3 system is the world's first approved transcatheter valve replacement ther. |
businesswire.com |
2025-04-14 12:00:00 |
Czytaj oryginał (ang.) |
| New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients |
CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology's (ACC) Annual Scientific Session & Expo, addressing the critical needs of patients with structural heart disease. Without treatment, 1 in 10 patients experiencing symptoms of severe aortic stenosis (AS) may die within five weeks. However, the symptoms of severe AS can be difficult to detect and may progress rapidly and unpredict. |
businesswire.com |
2025-03-31 18:00:00 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead |
Health Care and Energy sectors outperform in 2025, with the Health Care Select Sector SPDR Fund ETF up 7% YTD, while Edwards Lifesciences lags. Despite a solid Q4 earnings beat, EW's shares remain undervalued with a reduced P/E multiple of 33x, yielding a price target of $84. Key risks include slower TAVR growth in Japan and hospital demand uncertainties, but long-term sales growth targets remain optimistic. |
seekingalpha.com |
2025-03-23 01:51:13 |
Czytaj oryginał (ang.) |
| Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor |
SUNNYVALE, Calif.--(BUSINESS WIRE)--Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operation. |
businesswire.com |
2025-03-06 10:00:00 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference |
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Life. |
businesswire.com |
2025-02-25 09:05:00 |
Czytaj oryginał (ang.) |
| Should Edwards Lifesciences Stock Remain in Your Portfolio Now? |
EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm. |
zacks.com |
2025-02-20 12:26:23 |
Czytaj oryginał (ang.) |
| Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength |
On Tuesday, Edwards Lifesciences EW reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This represents a 9% year-over-year growth, supported by gains in all product groups. |
benzinga.com |
2025-02-12 16:51:10 |
Czytaj oryginał (ang.) |
| EW Stock Up on Q4 Earnings and Revenue Beat, Margins Crash |
Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart? |
zacks.com |
2025-02-12 10:35:23 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences Corporation (EW) Q4 2024 Earnings Call Transcript |
Edwards Lifesciences Corporation (NYSE:EW ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Mark Wilterding - Senior Vice President, Investor Relations Bernard Zovighian - Chief Executive Officer Scott Ullem - Corporate Vice President and Chief Financial Officer Daveen Chopra - Corporate Vice President, TMTT Larry Wood - Corporate Vice President and Group President of TAVR and SSH Conference Call Participants David Roman - Goldman Sachs Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Travis Steed - Bank of America Vijay Kumar - Evercore ISI Frederick Wise - Stifel Matthew Miksic - Barclays Matthew Taylor - Jefferies Joanne Wuensch - Citibank Mark Wilterding [Starts Abruptly] included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections. |
seekingalpha.com |
2025-02-11 23:46:43 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics |
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-11 21:01:32 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences beats profit estimate on strength in heart devices |
Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices. |
reuters.com |
2025-02-11 18:19:13 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences Reports Fourth Quarter Results |
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups Q4 TAVR sales grew 6%; constant currency2 sales grew 5% Q4 TMTT sales grew 88% to $105 million with increasing contribution to Edwards' growth Q4 EPS of $0.581; adjusted2 EPS of $0.59, driven by strong top-line performance Presen. |
businesswire.com |
2025-02-11 18:15:00 |
Czytaj oryginał (ang.) |
| Insights Into Edwards Lifesciences (EW) Q4: Wall Street Projections for Key Metrics |
Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024. |
zacks.com |
2025-02-06 12:21:33 |
Czytaj oryginał (ang.) |
| ITGR or EW: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integer (ITGR) and Edwards Lifesciences (EW). But which of these two stocks is more attractive to value investors? |
zacks.com |
2025-02-04 14:40:39 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences to Host Earnings Conference Call on February 11, 2025 |
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwar. |
businesswire.com |
2025-02-04 09:05:00 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences Is Poised For Solid Growth In 2025—Analyst Highlights TAVR Growth, Margin Expansion |
Edwards Lifesciences Corporation EW shares are trading higher on Thursday. |
benzinga.com |
2025-01-30 16:21:34 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences Q4 Earnings Set to Benefit From TAVR Growth |
Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter. |
zacks.com |
2025-01-30 13:25:32 |
Czytaj oryginał (ang.) |
| Analysts Estimate Edwards Lifesciences (EW) to Report a Decline in Earnings: What to Look Out for |
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-01-28 13:06:13 |
Czytaj oryginał (ang.) |
| Should Edwards Lifesciences Stock Stay in Your Portfolio Now? |
EW stock is on investors' radar courtesy to the promising structural heart opportunities post the divestment of the Critical Care arm. |
zacks.com |
2025-01-16 10:25:24 |
Czytaj oryginał (ang.) |
| Wedgewood Partners: Q4 And 2024 Top Performers And Detractors |
Texas Pacific Land and Taiwan Semiconductor Manufacturing were top contributors for both the quarter and the year, showcasing strong earnings growth and strategic market positioning. Despite Texas Pacific Land's strong performance, we sold our positions due to overvaluation driven by index additions, with plans to re-invest post-market correction. Edwards Lifesciences' EARLY TAVR trial results highlight significant potential for expanding aortic stenosis treatment, positioning the company for double-digit earnings growth in the coming years. |
seekingalpha.com |
2025-01-16 10:00:00 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived v. |
businesswire.com |
2025-01-07 09:05:00 |
Czytaj oryginał (ang.) |
| 4 Strong Stock Charts For 2025 (Technical Analysis) |
After analyzing weekly charts of all S&P 500 stocks, I found only 21 with “confidently optimistic” patterns, indicating a challenging market in 2025. My focus is on stocks with better odds of appreciating in 2025, not on beating the S&P 500 or achieving the highest returns. The four stocks I picked out from the crowd —Edwards Lifesciences, Jabil Inc., Kroger, and Darden Restaurants—show strong technical potential despite mixed fundamentals. |
seekingalpha.com |
2024-12-30 14:00:27 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in Edwards (EW) Stock? |
Investors need to pay close attention to Edwards (EW) stock based on the movements in the options market lately. |
zacks.com |
2024-12-20 12:00:45 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Edwards Lifesciences Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 13, 2024 – EW |
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=116540&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-13 19:50:00 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - EW |
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=116519&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-13 18:30:00 |
Czytaj oryginał (ang.) |
| Investors who lost money on Edwards Lifesciences Corporation (EW) should contact Levi & Korsinsky about pending Class Action - EW |
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=116460&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-13 13:45:00 |
Czytaj oryginał (ang.) |
| EW DEADLINE TODAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important December 13 Deadline in Securities Class Action – EW |
NEW YORK, Dec. 13, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both dates inclusive (the “Class Period”), of the important December 13, 2024 lead plaintiff deadline. |
globenewswire.com |
2024-12-13 13:23:00 |
Czytaj oryginał (ang.) |
| Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now? |
Edward Lifesciences' robust potential in Structural heart and long-term strategy instill optimism. |
zacks.com |
2024-12-13 12:15:25 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Shareholders of Edwards Lifesciences Corporation (EW) of a Class Action Lawsuit and an Upcoming Deadline |
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=116440&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-13 12:15:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Shareholders of Edwards Lifesciences Corporation (EW) of a Class Action Lawsuit and an Upcoming Deadline |
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=116381&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-13 11:15:00 |
Czytaj oryginał (ang.) |
| Contact Levi & Korsinsky by December 13, 2024 Deadline to Join Class Action Against Edwards Lifesciences Corporation (EW) |
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=116367&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-13 09:55:00 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 13, 2024 to Discuss Your Rights - EW |
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=116344&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-13 09:30:00 |
Czytaj oryginał (ang.) |
| FINAL REMINDER EW DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Edwards Lifesciences Corporation Investors to Participate in the Class Action Lawsuit |
NEW YORK CITY, NY / ACCESSWIRE / December 13, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards" or "the Company") (NYSE:EW) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Edwards securities between February 6, 2024, and July 24, 2024, inclusive (the "Class Period"). |
accesswire.com |
2024-12-13 09:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Edwards Lifesciences Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 13, 2024 - EW |
NEW YORK , Dec. 13, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024. |
prnewswire.com |
2024-12-13 07:45:00 |
Czytaj oryginał (ang.) |
| Edwards Lifesciences Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 13, 2024 to Discuss Your Rights - EW |
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=116279&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-12 20:00:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on Edwards Lifesciences Corporation(EW) should contact Levi & Korsinsky about pending Class Action - EW |
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=116263&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-12 18:30:00 |
Czytaj oryginał (ang.) |
| EW INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit |
NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Edwards Lifesciences Corporation (“Edwards” or “the Company”) (NYSE: EW) and certain of its officers. |
globenewswire.com |
2024-12-12 18:00:00 |
Czytaj oryginał (ang.) |
| Class Action Filed Against Edwards Lifesciences Corporation (EW) - December 13, 2024 Deadline to Join - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=116253&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-12 17:45:00 |
Czytaj oryginał (ang.) |
| EW FINAL DEADLINE FRIDAY: Edwards Lifesciences Investors have Until Tomorrow December 13 before Expiration of Court Deadline - Contact BFA Law |
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. |
accesswire.com |
2024-12-12 17:18:00 |
Czytaj oryginał (ang.) |
| The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Edwards Lifesciences Corporation (EW) |
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 13, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On July 24, 2024, Edwards Lifescien. |
businesswire.com |
2024-12-12 15:42:00 |
Czytaj oryginał (ang.) |
| Class Action Filed Against Edwards Lifesciences Corporation (EW) Seeking Recovery for Investors - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=116220&wire=1 or contact Joseph E. Levi, Esq. |
accesswire.com |
2024-12-12 14:15:00 |
Czytaj oryginał (ang.) |